Study: HPV vaccine by age 21 a sound public health investment
USA Today, August 21, 2008
A new economic analysis shows that the HPV vaccine could be a good financial investment in public health if given to preadolescent girls and women up to age 21. Authors of the study measured the Gardasil vaccine's value by calculating the cost of giving one person an extra healthy year of life and balancing the expense of vaccinations with the benefits of avoiding cancer, death, and related expenses.
- Will More Pioneer ACOs Defect?
- Charity HealthCare Conundrum Brewing Among Providers
- MU Final Rule Disappoints Some CIOs
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- Interventional Radiology No Longer a Sub-Specialty
- 'Terrible' Patient Becomes Dedicated Nurse
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- CNO Leads $1M Charge for New Scrubs, Uniforms
- mHealth Tackles Readmissions
- Acute Kidney Injury Gets New Focus